title: [Pharmaceutical care of a patient with oral anticoagulation and renal impairment].
abstract: Atrial fibrillation is one of the most important indications for oral anticoagulation. Besides vitamin K antagonists, the novel oral anticoagulants dabigatran, apixaban, edoxaban and rivaroxaban are one therapy option in patients with atrial fibrillation. The following case report describes an 83-year-old female patient treated with dabigatran for secondary stroke prevention. Due to different factors, the renal function of the patient decreases significantly (acute on chronic renal failure), resulting in a re-evaluation of the current treatment. This case report is an example of decision-making 'for and against' novel oral anticoagulants versus vitamin K antagonists.
authors.forename: Carina
authors.initials: C
authors.lastname: Hohmann
authors.forename: Roland
authors.initials: R
authors.lastname: Radziwill
authors.forename: Tobias
authors.initials: T
authors.lastname: Neumann-Haefelin
authors.forename: Peter
authors.initials: P
authors.lastname: Benöhr
mesh_terms: D000369:Aged, 80 and over; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D000069604:Dabigatran / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced* / Q000628:therapy*; D010593:Pharmaceutical Services
chemical_list: D000925:Anticoagulants; D000069604:Dabigatran